Switch theme
Sign up to access all valuation multiples
Sprint Bioscience AB is a Sweden based company involved in developing drugs focused on cancer and metabolism. The project portfolio of the company includes STK25, VPS34, and PIP4K2.
2009
27
LTM Revenue $7.4M
LTM EBITDA -$1.6M
$1.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sprint Bioscience has a last 12-month revenue (LTM) of $7.4M and a last 12-month EBITDA of -$1.6M.
In the most recent fiscal year, Sprint Bioscience achieved revenue of $6.9M and an EBITDA of -$1.8M.
Sprint Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sprint Bioscience valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.4M | XXX | $6.9M | XXX | XXX | XXX |
| Gross Profit | $7.2M | XXX | $3.9M | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | 57% | XXX | XXX | XXX |
| EBITDA | -$1.6M | XXX | -$1.8M | XXX | XXX | XXX |
| EBITDA Margin | -21% | XXX | -26% | XXX | XXX | XXX |
| EBIT | -$1.7M | XXX | -$2.0M | XXX | XXX | XXX |
| EBIT Margin | -23% | XXX | -30% | XXX | XXX | XXX |
| Net Profit | -$1.7M | XXX | -$1.9M | XXX | XXX | XXX |
| Net Margin | -23% | XXX | -28% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, Sprint Bioscience's stock price is SEK 1 (or $0).
Sprint Bioscience has current market cap of SEK 36.4M (or $3.8M), and EV of SEK 17.6M (or $1.8M).
See Sprint Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.8M | $3.8M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, Sprint Bioscience has market cap of $3.8M and EV of $1.8M.
Sprint Bioscience's trades at 0.3x EV/Revenue multiple, and -1.0x EV/EBITDA.
Equity research analysts estimate Sprint Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sprint Bioscience has a P/E ratio of -2.3x.
See valuation multiples for Sprint Bioscience and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.8M | XXX | $3.8M | XXX | XXX | XXX |
| EV (current) | $1.8M | XXX | $1.8M | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | 0.3x | XXX | XXX | XXX |
| EV/EBITDA | -1.2x | XXX | -1.0x | XXX | XXX | XXX |
| EV/EBIT | -1.1x | XXX | -0.9x | XXX | XXX | XXX |
| EV/Gross Profit | 0.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.3x | XXX | -2.0x | XXX | XXX | XXX |
| EV/FCF | -0.8x | XXX | -0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSprint Bioscience's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Sprint Bioscience's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sprint Bioscience's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sprint Bioscience and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -21% | XXX | -26% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 86% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sprint Bioscience acquired XXX companies to date.
Last acquisition by Sprint Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Sprint Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sprint Bioscience founded? | Sprint Bioscience was founded in 2009. |
| Where is Sprint Bioscience headquartered? | Sprint Bioscience is headquartered in Sweden. |
| How many employees does Sprint Bioscience have? | As of today, Sprint Bioscience has 27 employees. |
| Is Sprint Bioscience publicy listed? | Yes, Sprint Bioscience is a public company listed on STO. |
| What is the stock symbol of Sprint Bioscience? | Sprint Bioscience trades under SPRINT ticker. |
| When did Sprint Bioscience go public? | Sprint Bioscience went public in 2014. |
| Who are competitors of Sprint Bioscience? | Similar companies to Sprint Bioscience include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Sprint Bioscience? | Sprint Bioscience's current market cap is $3.8M |
| What is the current revenue of Sprint Bioscience? | Sprint Bioscience's last 12 months revenue is $7.4M. |
| What is the current EV/Revenue multiple of Sprint Bioscience? | Current revenue multiple of Sprint Bioscience is 0.2x. |
| Is Sprint Bioscience profitable? | Yes, Sprint Bioscience is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sprint Bioscience? | Sprint Bioscience's last 12 months EBITDA is -$1.6M. |
| What is Sprint Bioscience's EBITDA margin? | Sprint Bioscience's last 12 months EBITDA margin is -21%. |
| What is the current EV/EBITDA multiple of Sprint Bioscience? | Current EBITDA multiple of Sprint Bioscience is -1.2x. |
| What is the current FCF of Sprint Bioscience? | Sprint Bioscience's last 12 months FCF is -$2.2M. |
| What is Sprint Bioscience's FCF margin? | Sprint Bioscience's last 12 months FCF margin is -30%. |
| What is the current EV/FCF multiple of Sprint Bioscience? | Current FCF multiple of Sprint Bioscience is -0.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
